PET imaging of oestrogen receptors in patients with breast cancervan Kruchten, M., de Vries, E. G. E., Brown, M., Glaudemans, A. W. J. M., Dierckx, R. A. J. O., Schroder, C. P., Hospers, G. A. P. & de Vries, E., Oct-2013, In : Lancet Oncology. 14, 11, p. E465-E475 11 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Oestrogen receptors are overexpressed in around 70% of all breast cancers, and are a target for endocrine therapy. These receptors can be visualised on PET with use of 16 alpha-[F-18]-fluoro-17 beta-oestradiol (F-18-FES) as a tracer. Compared with biopsy, which enables assessment of individual sites, whole-body F-18-FES-PET enables quantification of oestrogen-receptor expression in all metastases. In several studies, measurement of tumour protein expression in oestrogen receptors by F-18-FES-PET, concurrent with biopsy, detected oestrogen-receptor-positive tumour lesions with a sensitivity of 84% and specificity of 98%. Roughly 45% of patients with metastatic breast cancer have discordant oestrogen-receptor expression across lesions (ie, F-18-FES-positive and F-18-FES-negative metastases). Low tumour F-18-FES uptake in metastases can predict failure of hormonal therapy in patients with oestrogen-receptor-positive primary tumours. Finally, F-18-FES-PET has shown that oestrogen-receptor binding capacity changes after intervention with hormonal drugs, but findings need to be confirmed. Factors other than oestrogen-receptor expression, including menopausal status and concomitant therapies, that can affect tumour F-18-FES uptake must be taken into account.
|Number of pages||11|
|Publication status||Published - Oct-2013|
- POSITRON-EMISSION-TOMOGRAPHY, HORMONE-BINDING GLOBULIN, IN-VIVO, FLUORINE-18-LABELED ESTROGENS, IMMUNOHISTOCHEMICAL ANALYSIS, METABOLIC FLARE, UTERINE-TUMORS, FES PET, TAMOXIFEN, ALPHA